Skip to main content
PLOS One logoLink to PLOS One
. 2024 Oct 25;19(10):e0312115. doi: 10.1371/journal.pone.0312115

The mechanism of NF-κB-TERT feedback regulation of granulosa cell apoptosis in PCOS rats

Haoxuan Xue 1,#, Zecheng Hu 2,#, Shun Liu 1, Shun Zhang 3, Wenqin Yang 1, Jiasi Li 1, Chulin Yan 1, Jiaming Zhang 1,*, Jing Zhang 1,*, Xiaocan Lei 1,*
Editor: Akingbolabo Daniel Ogunlakin4
PMCID: PMC11508119  PMID: 39453929

Abstract

Patients with Polycystic ovary syndrome (PCOS) have chronic low-grade ovarian inflammation. Inflammation can cause telomere dysfunction, and telomere and telomerase complex are also involved in regulating inflammation. However, the specific mechanisms of inflammatory signaling feedback and telomere-telomerase mutual regulation remain to be discovered. This study elucidates the role of Nuclear factor kappa-B (NF-κB)-Telomerase reverse transcriptase (TERT) feedback in PCOS granulosa cell apoptosis. Using letrozole and a high-fat diet, a PCOS rat model was established, along with a Lipopolysaccharide (LPS) -treated KGN cell inflammation model was established. NF-κB and TERT inhibitors (BAY 11–7082 and BIBR1532) were then administered to LPS-induced KGN cells. PCOS rats displayed disrupted estrous cycles, increased weight, elevated serum testosterone, cystic follicles, granulosa cell layer thinning, and reduced corpora lutea count (P are all less than 0.05). In PCOS rat ovaries, NF-κB, Interleukin-6 (IL-6), Tumor Necrosis Factor α (TNF-α), TERT, Bax, and Caspase-3 exhibited notable upregulation, while Bcl-2 decreased, with telomere elongation (P are all less than 0.05). There were significant correlations among NF-κB-related inflammatory factors, TERT and apoptotic factors, and they were positively correlated with Bax and Caspase-3, and negatively correlated with Bcl-2 (P are all less than 0.05). LPS-treated KGN cells demonstrated increased expression of inflammatory and pro-apoptotic factors, later restored post-treatment with NF-κB and TERT inhibitors (P are all less than 0.05). In conclusion, TERT may induce granulosa cell apoptosis by participating in the regulation of the NF-κB signaling pathway, thereby mediating the chronic inflammatory response of PCOS through downstream inflammatory factors IL-6 and TNF-α.

Introduction

PCOS is a common and complex endocrine, metabolic and psychological disorder affecting 5–18% of women in reproductive age [1, 2]. The Rotterdam criteria (2003) are commonly employed for diagnosing PCOS, requiring the presence of at least two of the following three features: clinical and/or biochemical hyperandrogenism, irregular ovulation or anovulation, and polycystic ovarian morphology (PCOM) [1, 3]. The cause of PCOS is multifaceted, including strong epigenetic and genetic influences, accompanied by hyperandrogenism, chronic inflammation, obesity, insulin resistance and abnormal lipid metabolism [46]. Research indicates that PCOS is characterized by a proinflammatory state, with emerging evidence supporting the presence of chronic low-grade ovarian inflammation in affected women [7, 8]. Patients with PCOS have significantly increased levels of proinflammatory factors, such as TNF-α, IL-6 and so on [911]. The pathway used to control TNF-α and IL-6 is through the Regulation of NF-κB [12]. What’s more, It has been shown that the NF-κB plays an important role in the inflammatory state of patients with PCOS [7].

Telomeres are specific structures located at the ends of linear chromosomes in eukaryotes. The maintenance of telomere length is essential for the normal structure and function of telomeres and the integrity and stability of chromosome ends [13]. Each cell division shortens the length of telomere 5’-TTAGG-3’ sequence, which eventually leads to apoptosis or senescence [14]. Telomerase is a ribonucleoprotein complex comprising TERT, telomerase RNA component (TERC), and telomerase-associated proteins (TEP) [15]. TERC was used as a template for telomerase. TERT acts as a catalytic subunit to reverse transcribe telomeric DNA and maintain telomere length [16]. The expression level of TERT is the main determinant of telomerase activity [17]. The initiation of telomerase is a prerequisite for maintaining telomere length and genome integrity and achieving cell immortalization and malignant transformation [18]. Most human somatic cells do not show telomerase activity, and a few cells with vigorous division, such as stem cells [19], tumor cells [18], and germ cells [20], express telomerase activity to varying degrees. The study included women aged 20 to 30 years, comprising 40 PCOS patients and 35 healthy controls for comparison. It was found that the telomere length of granulosa cells in PCOS group was significantly longer than that in Control group, while the telomere length of peripheral blood leukocytes was not different from that in Control group [21]. Another study showed that 75 PCOS patients and 81 non-PCOS women were included in the study, and it was found that there was no significant difference in leukocyte telomere length between the Control group and PCOS patients. Interestingly, however, when comparing the telomere length of granulosa cells between Controls and PCOS patients, the telomere length of PCOS patients was significantly longer. The p values remained significant after adjusting for age and body mass index [22]. Pedroso et al. proposed that the maintenance of telomere length in cumulus cells of PCOS patients might be attributed to elevated telomerase TERT activity [23].

It has been proved that telomerase can regulate NF-κB signaling pathways, resulting in the stimulation of TNF-α and IL-6 [24], and telomerase activity in cumulus cells was higher in the PCOS group [23]. TERT is a component of telomerase, and it interacts with NF-κB [25]. With Given this, it is crucial to ascertain whether there is an association between NF-κB-related chronic low-grade inflammation and TERT expression in PCOS ovaries. Recent studies have focused on the function of granulosa cells (GCs), which play an important role in folliculogenesis and follicle maturation [26]. Apoptosis is a form of programmed cell death, with the anti-apoptotic protein Bcl-2 and the pro-apoptotic protein Bax being the most representative. An imbalance in the interaction between Bcl-2 and Bax is a primary cause of apoptosis [27]. The Caspase family also plays a significant role in the molecular mechanisms that induce apoptosis, serving as the final common pathway for various apoptotic signaling routes [28]. Apoptosis has been observed in GCs of PCOS patients [29]. Bax and Caspase-3 and Bcl-2 play a crucial role in regulating the growth and apoptosis of GCs during follicular development [27, 29, 30]. And chronic inflammation can cause continuous oxidative stress, leading to cell apoptosis [31]. Moreover, it has been reported that chronic low-grade inflammation in PCOS eventually leads to granulosa cell apoptosis [32]. Studies have confirmed that the chronic inflammatory response in PCOS patients can affect the changes in telomere length and telomerase activity [33]. Because the expression of TERT directly reflects the level of telomerase activity [13], and the activation of NF-κB signaling pathway can cause the release of TNF-α and IL-6. Hence, TERT may mediate chronic inflammatory response and induce apoptosis of granulosa cells by participating in the regulation of NF-κB signaling pathway. Therefore, this study will investigate the interaction between inflammation and telomeres and how this feedback influences granulosa cell apoptosis, ultimately leading to impaired follicular development in PCOS rats.

Materials & methods

Animals and experiment protocol

Female Sprague Dawley (SD) rats (n = 12, 5 weeks old, 172 ± 8g) were obtained from Hunan SJA Laboratory Animal Co.Ltd (Changsha, China). The rats were reared at 25°C, 12 h light/dark cycle, and enough food and water were provided for free access. After one week of adaptive feeding, the rats were randomly divided into control group (n = 6) and PCOS group (n = 6). The control group were supplied with standard pellets of feed for 30 days; the PCOS group were fed with a high-fat diet (HFD, consisting of 61.5% standard food, 12% lard, 5% sucrose, 5% milk powder, 5% peanut, 10% egg, 1% sesame oil, 0.5% salt) and letrozole (1 mg/kg/day, dissolved in 1% carboxymethylcellulose [CMC] for 30 days to establish the PCOS model [34]. All rats were anesthetized with an intraperitoneal injection of 20% urethane (0.6 mL 100 g-1) before euthanasia. Body weight was determined at the end of modeling. Blood samples were collected after anesthetization. Ovaries were isolated, weighed, and the left ovaries of rats from each group was fixed in 4% paraformaldehyde overnight before being embedded in paraffin. The right ovaries of rats from each group were stored at −80°C for molecular analysis. All animal experiments were performed in accordance with Regulations on the Administration of Laboratory Animals of University of South China (Revised in 2017) and approved by the Animal Ethics Committee of University of South China (No. SYXK2020-0002).

Vaginal smears and estrous cycle determination

Vaginal smears were taken daily between 11:00 am and 12:00 for 10 days before the end of modeling [35]. The estrous cycle stage was determined by observation of the vaginal smears using a light microscope (Zeiss,Germany). The stages of the estrous cycle were determined by identifying predominant cell types of cells present in rat vaginal smears [3639]: nucleated epithelial cells (proestrus); cornified cells (estrus); and mixed cells (nucleated, cornified, leucocytes) (metestrus); leucocytes (diestrus).

Serum hormone measurement

All rats were anesthetized with 20% urethane,and the whole blood sample was collected from the abdominal aorta of rats immediately. The serum was further isolated by centrifuging at 2000 rpm for 10 min at 4°C, and stored at −80°C for further determination. The levels of serum T, follicle stimulatinghormone (FSH) and luteinizing hormone (LH) were determined with radioimmunoassay (Beijing North Institute of Biotechnology Co., Ltd., Beijing, China).

Hematoxylin-eosin (H&E) staining

The left ovaries of rats from each group was fixed in 4% paraformaldehyde overnight before being embedded in paraffin, and then were sequentially sectioned with 5 μM- slices for hematoxylin and eosin (H&E) staining in order to examine the pathological structural alterations of the ovary.

Real-Time Quantitative PCR (RT-qPCR) analysis

Total RNA from ovary tissues and cells was extracted using TRIZOL reagent (15596026, Thermo Fisher Scientific, Shanghai, China) and cDNA was synthesized with TransScript One-Step gDNA Removal and cDNA Synthesis SuperMix Kit (TRAN, Beijing, China). Real-time PCR analyses were performed with the 2× Universal SYBR Green Fast qPCR Mix Kit (RK21203, ABclonal) and Applied Biosystems QuantStudio 3 (Thermo Fisher Scientific). GAPDH was used as the reference and The critical threshold cycle (Ct) [38] value was determined for each reaction, which was transformed into relative quantification data using the 2−ΔΔCt method. The experimental primers were Human IL-6 (HQP009670, GeneCopoeia), Human TERT (HQP018018, GeneCopoeia) and Human TNF-α (HQP018141, GeneCopoeia).The primer sequences used for amplification are shown in Table 1.

Table 1. Primer sequences used for the qRT-PCR analysis.

Gene ID Sequence GeneBank Accession NO.
Rat NF-κB Forward AGCCACTGCCTTCCCTACTTC NM_001276711.2 
Reverse GGTCCTTAGCCCACTCCTTCTG
Rat TNF-α Forward GTCCCAACAAGGAGGAGAAGT NM_012675.3
Reverse CTGGTATGAAATGGCAAATCG
Rat TERT Forward AGTGGTGAACTTCCCTGTGG NM_053423.2
Reverse CAACCGCAAGACTGACAAGA
Rat Bax Forward GAGACACCTGAGCTGACCTT XM_032913059
Reverse TCCATGTTGTTGTCCAGTTC
Rat Bcl-2 Forward AGTACCTGAACCGGCATCT NM_016993
Reverse TCTTCAGAGACAGCCAGGA
Rat Caspase-3 Forward CCGGTTACTATTCCTGGAGA XM_006253130
Reverse TAACACGAGTGAGGATGTGC
Rat GAPDH Forward TACACTGAGGACCAGGTTG XM_032916238
Reverse CCCTGTTGCTGTAGCCATA
Homo NF-κB Forward CTGCCGGGATGGCTTCTAT NM_001165412.2
Reverse CCGCTTCTTCACACACTGGAT
Homo Bax Forward GCGACTGATGTCCCTGTCT NM_001291430
Reverse TGAGTGAGGCGGTGAGC
Homo Bcl-2 Forward CCCTGTGGATGACTGAGTACC NM_000633
Reverse AGACAGCCAGGAGAAATCAAA
Homo Caspase-3 Forward CAGTGATGCTGTGCTATGAAT NM_001354783
Reverse CAGATGCCTAAGTTCTTCCAC
Homo GAPDH Forward GAGTCCACTGGCGTCTTCAC NM_001357943.2
Reverse GAGGCATTGCTGATGATCTTGAG

Western blot analysis

Ovarian tissue and KGN cell lysates were extracted by RIPA lysis buffer (CWBIO, Beijing, China) and PMSF (Solarbio). The protein concentration was detected by a BCA Protein Assay Kit (CWBIO). Denatured proteins were separated by 10% SDS-PAGE, electrophoretically transferred onto polyvinylidene fluoride membranes (Meck Millipore, Merck & Co., Inc., NJ, USA). Then, transferred membranes were blocked by PBST (phosphate buffered saline [PBS] with 0.1% Tween-20) containing 5% skim milk for 2 h. The membranes were respectively incubated with antibodies against NF-κB p65 (1:1000 dilution, #8242, Cell Signaling Technology), IL-6 (1:1000 dilution, TD6087, Abmart Shanghai Co.,Ltd.), TNF-α (1:1000 dilution, PY19810, Abmart Shanghai Co.,Ltd.), TERT (1:1000 dilution, TD7129, Abmart Shanghai Co.,Ltd.), Bax (1:1000 dilution, T40051, Abmart Shanghai Co.,Ltd.), Bcl-2 (1:1000 dilution, 13–8800, Thermo Fisher Scientific, Shanghai, China), Caspase-3 (1:1000 dilution, #9662, Cell Signaling Technology) and β-Tubulin (1:5000 dilution, R20005, Abmart Shanghai Co.,Ltd.) overnight at 4°C, followed by HRP-conjugated affinipure goat anti-mouse IgG (H+L) (1:5000 dilution, SA00001-1; Protein Tech Group Inc., USA) or goat anti-rabbit IgG (H+L) (1:5000 dilution, SA00001-2; Protein T ech Group Inc.) for 2h at room temperature. Finally, eECL (CW0049M, CWBIO) was added, and the Tanon-5500 Chemiluminescence Imaging System was used to detect the chemiluminescence of protein bands. Finally, blotting images were quantified using Image J analysis software (JAVA image processing program, NIH, Bethesda, USA).

Immunohistochemistry (IHC)

Samples of ovarian tissues was fixed in 4% paraformaldehyde overnight before being embedded in paraffin, and then were sequentially sectioned with 5 μM- slices. The endogenous peroxidase activity was blocked by 3% H2O2 for 30 min. The slices were put in the microwave in 0.1 M sodium citrate (pH 6.0) three times for antigen retrieval, permeabilized with 1% T riton X-100 and PBST for 30 min, and blocked with 5% bovine serum albumin for 45 min. Subsequently, the slides were incubated in a humidity chamber at 4°C overnight with primary antibody NF-κB p65 (1:400 dilution, #8242; Cell Signaling Technology), IL-6 (1:100 dilution, TD6087, Abmart Shanghai Co.,Ltd.), TNF-α (1:200 dilution, PY19810, Abmart Shanghai Co.,Ltd.), TERT (1:100 dilution, TD7129, Abmart Shanghai Co.,Ltd.), Bax (1:100 dilution, T40051, Abmart Shanghai Co.,Ltd.), Bcl-2 (1:200 dilution, 13–8800, Thermo Fisher Scientific, Shanghai, China), Caspase-3 (1:100 dilution, #9662, Cell Signaling Technology). After washing with PBST, the slices were incubated with Biotin-SP-conjugated Affinipure Rabbit Anti-Goat IgG(H+L) (1:200, SA00004–4; Protein Tech Group Inc.) at room temperature and 37°C for 45 min. The slices were then incubated with HRP-conjugated Streptavidin (1:200, SA00001–0; Protein Tech Group Inc.) at 37°C for 45 min. The slides were finally treated with 3,3-diamino-benzidine (DAB) (20× Metal Enhanced DAB Substrate Kit; Solarbio) to allow the brown staining of the positive cases. PBST was used as a negative control. Finally, the stained sections were observed and photographed under a light microscope (BX43, Olympus).

Measurement of ovarian telomere length

Total RNA was extracted from ovarian tissue using TRIZOL reagent and reverse transcribed into cDNA. DNA was then used as a template for Rt-PCR analysis. The PCR reaction system consisted of 5 uL of 2×ChamQ SYBR qPCR Master Mix, 1 μL of primer mix, 1 uL of template DNA, and 3 uL of ddH2O. The reaction conditions for telomere gene Tel and reference gene 36B4 were basically the same, with 32 cycles for telomere gene and 40 cycles for reference gene, and melting curve analysis was performed after PCR reaction. Telomere length was analyzed by relative quantification method: Ct values of target gene and reference gene were obtained, ΔCt = CtTel_Ct36B4, telomere/single copy reference ratio (T/S) was calculated: 2-Ct = (2CtTel/2Ct36B4)-1, the relative T/S ratio 2-ΔΔCt = 2-(ΔCt1-ΔCt2), this ratio corresponds to the relative telomere length of the samples, where ΔCt1 is the T/S of each sample and ΔCt2 is the T/S of the reference sample. The primer sequences used for amplification are shown in Table 2.

Table 2. Primer sequences used for telomere length analysis.

Gene ID Sequence
Rat Telomere Forward GTAATTGCGTAAGACTTAAAACC
Reverse CCTAGAAATAAGAGGATTTAAACC
Rat 36B4 Forward ACTGGTCTAGGACCCGAGAAG
Reverse TCAATGGTGCCTCTGGAGATT

Cell viability assay

Cell viability was measured by Cell Counting Kit-8 Solution Reagent (CCK-8, Beyotime, China). Briefly, cells were seeded in 96-well plates, and Wells without cells were set as blank control, positive control, and different concentrations of BAY 11-7082(0, 5, 10, 5, and 20 μm) and BIBR1532(0, 10, 20, 40, and 80 μM) for culture. Cell viability was examined by following standard procedures. Experiments were performed in triplicate.

Cell culture and treatment

Human ovarian granulosa-like tumor cell line KGN, which originated from a stage Ⅲ invasive ovarian granulosa cell carcinoma in a 63-year-old woman, this cell line In review was considered as a model for understanding the regulation of steroidogenesis, cell growth, and apoptosis in human granulosa cells. In this study, KGN cells were purchased from Zhejiang Meisen Cell Technology Co., LTD (CTCC-003-0105). KGN cells were cultured with Dulbecco’s Modified Eagle’s Medium-high glucose (DMEM, Sigma, USA) supplemented with 10% Fetal Bovine Serum (FBS, Invitrogen 115 Gibco, USA) and maintained in an atmosphere of 5% CO2 at 37°C. KGN cells were plated in 6 cm plates at 106 per well. After starving for 24 h, the cells were treated without or with LPS (100 μg/mL) (I2643; Sigma, USA), BAY 11–7082 (10 μg/mL) (HY-13453, MCE, USA), and C(40 μg/mL) (HY-17353, MCE, USA) for 24 h.

Flow cytometry was employed to detect cell apoptosis

KGN cells from drug-treated groups were digested using trypsin without EDTA (Biosharp, China). After terminating digestion, cell suspensions were collected in centrifuge tubes and centrifuged at 800 rpm for 5 minutes at room temperature, and the supernatant was discarded. The cells were then washed with pre-chilled 1×PBS (4°C) and centrifuged at 800 rpm for 5 minutes. FITC-conjugated Annexin-V apoptosis detection kit (556547, Becton Dickinson, USA) was used to label KGN cells from each group for subsequent flow cytometry analysis.

Statistical analysis

Data were analyzed using GraphPad Prism 8.0 (GraphPad Software, CA, USA) and presented as the mean ± standard deviation. Significant differences between/within groups were evaluated by the unpaired t-test or one-way ANOVA followed by Bonferroni ‘s post-hoc test. Correlation between variables was determined by Pearson’s correlation coefficient. P value <0.05 was considered to be statistically significant.

Results

Letrozole and high-fat diet induced clinical PCOS-like changes in SD rats

As mentioned above, the pathogenesis of PCOS has been studied from many angles, but remains unexplored the role produced by the NF-κB-TERT pathway in the pathogenesis of PCOS, so we aims to elucidate this aspect in the current study. Therefore, a PCOS rat model was established by the treatment of HFD and letrozole. As shown in Fig 1A and 1B, the body weight and the ovarian weight of rats in the PCOS group was significantly increased than that of the control group. Compared with the control group, the serum levels of testosterone was significantly higher in PCOS group (Fig 1C).Estrous cycle disorder is one of the main characteristics of PCOS [3840]. The normal estrous cycle in rats averages 4–5 days, which is generally divided into four stages—Proestrus, Estrus, Metestrus, and Diestrus [36]. As shown in Fig 1D and 1E, the control rats had a regular estrous cycle. Briefly, samples dominated by nucleated epithelial cells indicated the proestrus stage, and those with primarily cornified squamous epithelial cells indicated the estrus stage. The metestrus stage was indicated by mixed cells (nucleated, cornified, leucocytes), while the diestrus stage was dominated by leukocytes. Compared with control rats, the PCOS rats displayed disrupted estrous cycles, which comprised only the metestrus or diestrus phases. Appearance of representative ovaries. Compared with the control group, multiple follicles with cystic expansion presented vacuolated and disorganized structure (Fig 1F). Assessment of the ovarian morphology showed a significant decrease in the number of follicles and corpus luteum in PCOS rats compared with those in the controls, whereas antral follicles with cystic expansion were increased. The thickness of the granulosa cell layer was also reduced (Fig 1G and 1H).These results proved that we successfully constructed the PCOS rat model.

Fig 1. Effects of letrozole and high-fat diet induction on body weight, ovarian weight, serum hormone levels, estrous cycle, and ovarian morphology.

Fig 1

A: Body weight of each group (n = 6 per group, day 60). B: Bilateral total ovarian weight in each group. C: Serum testosterone levels in each group (n = 6 per group). D: Cytological assessment of vaginal smears (n = 5 per group, day 51–60). E: Line chart of estrous cycle (n = 5 per group, day 51–60). F: Ovarian morphology of each group. G: HE staining scan and magnification of ovarian sections in each group (n = 6 per group, scale bar in upper is 500 μm). The lower panel show the higher magnification of the box area in the upper panel respectively. H: Counts of cystic follicles and corpus luteum (n = 6 per group). CL: corpus luteum; GC: granulosa cells. Significant differences between groups were indicated as **P < 0.01 and ***P < 0.001.

Letrozole and high-fat diet induced PCOS increased the expression of NF-κB-related inflammatory factors and TERT in ovaries

Subsequently, to investigate the association between NF-κB-TERT feedback regulation and ovarian granulosa cell apoptosis in PCOS rats, we initially assessed the levels of NF-κB-related inflammatory factors in ovarian tissues from both groups to elucidate the link between chronic low-grade inflammation in the ovary and TERT expression. The qRT-PCR results demonstrated an upregulation of NF-κB, IL-6, TNF-α, and TERT in PCOS rats (Fig 2A). Western blot analysis further confirmed the elevated levels of NF-κB, IL-6, TNF-α, and TERT in the PCOS group compared to the control group (Fig 2B and 2C). Immunohistochemistry analysis also supported these findings by revealing increased expression of NF-κB, IL-6, TNF-α, and TERT in the PCOS group (Fig 2D). Our findings suggest that induction of PCOS through letrozole administration and a high-fat diet leads to enhanced expression of NF-κB-related inflammatory factors as well as TERT within the ovary. Additionally, telomere length was determined using qPCR analysis on ovarian granulosa cells from PCOS rats. utilized telomere-specific primers for this analysis. As depicted in Fig 2E, Compared with the control group, the telomere length of the cells in the ovaries increased by 1 to 2 times. These results indicate that the activity of inflammatory markers in ovarian cells of PCOS rats is increased and TERT function is increased.

Fig 2. The levels of NF-κB related inflammatory factors, TERT expression and telomerase relative length are significantly increased in the ovarian tissue of PCOS rats.

Fig 2

A: The expression changes of NF-κB, IL-6, TNF-α and TERT at mRNA level were detected by qRT-PCR (n = 3 per group). B-C: Western blotting was used to detect the protein expression of NF-κB, IL-6, TNF-α, and TERT, and ImageJ was used for quantitative analysis (n = 3 per group). D: Immunohistochemistry was used to detect the expression changes of NF-κB, IL-6, TNF-α and TERT at protein level (n = 4 per group), the lowest panel shows the negative control. E: Telomere length quantitative qRT-PCR results showed increased telomere length in the ovarian region of PCOS rats compared to controls (n = 3 per group). T/S ratio (telomere/single gene ratio); Data were presented as mean ± SEM. Significant differences were respectively presented as *P < 0.05, **P < 0.01, ***P < 0.001.

The increase of ovarian cell apoptosis in PCOS rats is positively correlated with NF-κb related inflammatory factors, TERT and apoptosis factors

To further validate our hypothesis, we proceeded to investigate the expression of apoptotic factors at both mRNA and protein levels. In comparison with the control group, we observed a significant increase in the mRNA levels of Bax and caspase-3, along with a decrease in Bcl-2 mRNA level in GCs from the PCOS group (Fig 3A). Additionally, compared to the control group, GCs from the PCOS group exhibited elevated protein levels of Bax and caspase-3, while showing reduced levels of Bcl-2 (Fig 3B and 3C). Immunohistochemical staining analysis yielded consistent results (Fig 3D). Subsequently, we conducted an extensive analysis to explore any potential relationship between NF-κB-related inflammatory factors, TERT, and apoptotic factors in PCOS; aiming to elucidate whether chronic low-grade ovarian inflammation and up-regulation of TERT are associated with apoptosis. Fig 3E demonstrates a significant correlation among NF-κB-related inflammatory factors, TERT, and apoptotic factors. Specifically, Nf-κb-related inflammatory factors and TERT displayed positive correlations with pro-apoptotic markers such as Bax and Caspase-3; conversely exhibiting negative correlations with anti-apoptotic factor Bcl-2. These findings indicate that ovarian granulosa cells undergo apoptosis in PCOS rats, and underscore a positive correlation between NF-κB-related inflammatory factors, TERT, and apoptosis.

Fig 3. Apoptosis is increased in the ovary of PCOS rats, and there is a correlation between NF-κB-related inflammatory factors, TERT and apoptosis factors.

Fig 3

A: The expression changes of Bax, Bcl-2 and Caspase-3 at the mRNA level were detected by qRT-PCR (n = 3 per group). B-C: Western blotting was used to detect the changes in the expression of Bax, Bcl-2 and caspase-3 at the protein level, and ImageJ was used for quantitative analysis (n = 3 per group). D: The expression of Bax, Bcl-2 and caspase-3 at the protein level was detected by immunohistochemistry (n = 4 per group), the lowest panel shows the negative control. E: Correlation analysis of inflammatory factors NF-κB, IL-6, TNF-α, telomerase reverse transcriptase TERT and apoptosis-related factors Bax, Bcl-2, Caspase-3 in ovarian tissue of rats in each group, Correlation between variables was determined by Pearson’s correlation coefficient. P<0.05 was considered to be statistically significant. Data were presented as mean ± SEM. Significant differences were respectively presented as *P < 0.05 and **P < 0.01.

After LPS stimulation, NF-κb-related inflammatory factors, hTERT expression and apoptosis of KGN cells increased, and there was a correlation among three

The results of animal experiments demonstrated a significant correlation between NF-κB, its downstream inflammatory factors, and TERT with apoptosis-related factors in PCOS rats. To further investigate the relationship between NF-κB-TERT regulation and PCOS granulosa cell apoptosis, KGN cells were treated with LPS at a concentration of 1μg/ml to establish an inflammatory cell model. This model was divided into two groups: control group and LPS group. qPCR assay was employed to assess changes in mRNA expression levels of NF-κB, its downstream inflammatory factors, hTERT, and apoptosis-related factors in both groups. In the LPS group, there was a significant upregulation of mRNA expression for NF-κB p65 and its downstream inflammatory factors IL-6, TNF-α, hTERT as well as pro-apoptotic factors Bax and Caspase-3 (Fig 4A). Conversely, the expression of anti-apoptotic factor Bcl-2 was significantly downregulated. Based on our previous animal experiments which revealed a significant correlation between NF-κB, its downstream inflammatory factors, TERT with apoptosis-related factors in PCOS rat ovaries; we found that NF-κB along with its downstream inflammatory factors were positively correlated with pro-apoptotic markers while negatively correlated with anti-apoptotic markers. To validate these findings from animal experiments further analysis was conducted to explore the association between NF-kappa B along with its downstream inflammatory mediators (IL-6, TNF-α), hTERT and apoptotic markers within KGN cells. As depicted in Fig 4B it is evident that there exists a significant correlation among NF-kappa B along with its downstream inflammatory mediators (IL6, TNF-α) as well as hTERT concerning apoptotic markers. Specifically, NF-κB p65, IL-6, TNF-α, and hTERT were positively associated with pro-apoptotic proteins such as Bax and Caspase-3, while exhibiting a negative association with the anti-apoptotic protein Bcl-2. These results indicated that LPS-induced KGN cells exhibited increased expression of inflammatory factors and apoptosis, and NF-κB-related inflammatory factors and TERT were positively correlated with apoptosis.

Fig 4. LPS treatment increases the expression of NF-κB-related inflammatory factors, hTERT and cell apoptosis in KGN cell and correlation between NF-κB-related inflammatory factors, TERT and cell apoptosis factors after LPS stimulation in KGN cell.

Fig 4

A: The mRNA expression of NF-κB, IL-6, TNF-α, TERT, Bax, Bcl-2 and Caspase-3 in KGN cells in each group was detected by qRT-PCR. B: The correlation between inflammatory factors (NF-κB, IL-6, TNF-α, TERT) and apoptosis-related factors (Bax, Bcl-2, Caspase-3) in KGN cells after LPS stimulation was analyzed. Pearson correlation coefficient was used to determine the correlation between variables. P<0.05 was considered statistically significant. Data were presented as mean ± SEM. Significant differences were respectively presented as *P < 0.05 and **P < 0.01.

Inhibition of NF-κB and TERT reduced the expression of NF-κB-related inflammatory factors and TERT in KGN cells treated with LPS

To further elucidate the mechanism underlying NF-κB-TERT feedback regulation on apoptosis of ovarian granulosa cells in PCOS rats, we treated LPS-induced KGN cells with 10μg/ml BAY 11–7082 and 40 μg/ml BIBR1532, respectively. Experimental groups included Control (control), LPS (LPS induction only), LPS+NF-κB inhibitor (LPS induction + NF-κB inhibitor treatment), and LPS+TERT inhibitor (LPS induction + TERT inhibitor treatment). qPCR and Western Blot analyses were employed to assess the expression levels of NF-κB, its downstream inflammatory factors, and TERT in these four groups. Our results demonstrated a significant upregulation of NF-κB p65 along with its downstream inflammatory factors IL-6, TNF-α, and TERT in the LPS group compared to the control group. However, both the groups treated with NF-κB inhibitor BAY 11–7082 and TERT inhibitor BIBR1532 exhibited a significant downregulation of NF-κB p65 as well as its downstream inflammatory factors IL-6, TNF-α, and hTERT when compared to the LPS group (Fig 5A and 5B). To further investigate changes induced by LPS in KGN cells regarding inflammatory factors secretion, we quantified TNF-α and IL-6 levels in cell culture medium using ELISA assay (Fig 5C). Our findings revealed significantly increased levels of these inflammatory factors in the LPS group compared to both control and inhibitor groups.

Fig 5. Changes in the expression of NF-κB-related inflammatory factors, TERT and telomerase activity in KGN cells in each group.

Fig 5

A: The mRNA expression of NF-κB, IL-6, TNF-α and TERT in KGN cells of each group was detected by qRT-PCR. B-C: Western blotting detected the expression of NF-κB, IL-6 and TNF-α proteins in KGN cells of each group, and ImageJ was used for quantitative analysis. D: ELISA was used to detect the content of inflammatory factors (TNF-ɑ, IL-6) in the cell culture medium. Data were presented as mean ± SEM. Significant differences were respectively presented as *P< 0.05, **P< 0.01, ***P<0.001.

Inhibition of NF-κB and TERT reduced apoptosis in LPS-treated KGN cells

Upon observing a significant correlation among inflammatory factors, TERT, and apoptotic factors in KGN cells following LPS induction, we initiated further investigations into the alterations of apoptosis-related factors in these cells upon treatment with the NF-κB inhibitor BAY 11–7082 and the TERT inhibitor BIBR1532. The expression of apoptosis-related factors was assessed using qPCR and Western Blot analysis across four cell groups (Fig 6A–6C). Our findings revealed that compared to the control group, pro-apoptotic factors Bax and Caspase-3 were significantly up-regulated while anti-apoptotic factor Bcl-2 was significantly down-regulated in the LPS group. However, when compared to the LPS group, both NF-κB inhibitor BAY 11–7082 and TERT inhibitor BIBR1532 exhibited significant down-regulation of pro-apoptotic factors Bax and Caspase-3 along with a notable up-regulation of anti-apoptotic factor Bcl-2. Moreover, we employed Annexin V combined with propidium iodide labeled flow cytometry for apoptosis detection, followed by result analysis using FlowJo software. According to the results depicted in Fig 6D, the apoptosis rate of KGN cells induced by LPS significantly increased compared to the control group. However, the apoptosis rate of LPS-induced KGN cells treated with NF-κB and TERT inhibitors approached that of the control group. These results suggest that chronic low-grade inflammation in PCOS patients triggers a positive feedback regulation of the NF-κB-TERT pathway, which subsequently leads to the release of downstream inflammatory factors IL-6 and TNF-α, thereby increasing the expression levels of pro-apoptotic markers BAX and Caspase-3. At the same time, it decreases the expression level of anti-apoptotic marker Bcl-2, which eventually leads to the apoptosis of granulosa cells.

Fig 6. Changes in the expression of apoptosis-related factors Bax, Bcl-2, and Caspase-3 in KGN cells in each group.

Fig 6

A: The mRNA expression of Bax, Bcl-2 and Caspase-3 in KGN cells of each group was detected by qRT-PCR. B-C: Western blotting detected the expression of Bax, Bcl-2 and Caspase-3 proteins in KGN cells of each group, and ImageJ was used for quantitative analysis. D: The apoptosis of KGN cells in each group was detected by flow cytometry. Data were presented as mean ± SEM. Significant differences were respectively presented as *P< 0.05 and ***P<0.001.

Discussion

PCOS is characterized by the presence of stunted follicles in the enlarged ovaries of affected females, typically accompanied by menstrual irregularities, hyperandrogenism, metabolic abnormalities, and mental disorders [41]. Currently, PCOS is the most common cause of female anovulation and infertility [42]. PCOS is a multifaceted systemic disease that significantly impacts women’s overall health and well-being throughout their lifespan. It not only affects the reproductive endocrinology of young women, but also involves multiple systems such as glucose and lipid metabolism, cardiovascular and skin. However, the mechanism of polycystic ovary syndrome is still unclear, so it is urgent to clarify the exact pathogenesis of PCOS, improve the diagnostic criteria of PCOS, and develop more targeted drugs.

In recent years, the role of chronic low-grade inflammation in the pathogenesis of PCOS has attracted increasing attention. Recent studies have shown that inflammatory processes are closely related to ovulation and play an important role in ovarian follicle dynamics. A large body of evidence has shown that hyperandrogenism in PCOS patients is closely related to inflammation-related genes such as TNF-α, Tnf receptor 2 (TNFR2) and IL-6 [10]. Moreover, numerous studies have identified a strong association between PCOS-related inflammatory responses and visceral adipose tissue [43]. Abdominal obesity is common in PCOS patients. Visceral adipose tissue recruits immune cells by increasing the production and secretion of inflammatory factors monocyte chemoattractant proteins (MCP), leading to inflammatory response and maintaining the inflammatory state of adipocytes [44]. Hyperglycemia associated with insulin resistance in PCOS patients can also induce inflammatory responses, leading to NF-κb activation and oxidative stress. Oxidative stress is the key link of chronic low-grade inflammation in PCOS, and is closely related to the expression of related pro-inflammatory factors [44]. Contemporary biomedical research indicates that sustained activation of the inflammatory response in ovarian tissue plays a pivotal role in the reproductive endocrine dysfunction of PCOS [45]. On the one hand, the release of inflammatory cytokines in ovarian tissue directly damages granulosa cells, which is not conducive to the development of follicles, and then leads to rare ovulation or anovulation. On the other hand, it stimulates androgen production, which further aggravates ovulation disorder and leads to systemic hyperandrogenism. Simultaneously, the activation of the inflammatory response can interfere with insulin signal transduction, reducing insulin sensitivity and leading to insulin resistance and compensatory hyperinsulinemia. In conclusion, PCOS is closely linked to chronic low-grade inflammation.

As shown in the present study, we examined the changes in the expression levels of NF-κB and its downstream target genes IL-6 and TNF-α in ovarian granulosa cells of PCOS rats. The results showed that compared with the control group, the expression levels of NF-κB P65 and its downstream inflammatory factors IL-6 and TNF-α in the ovarian tissue of PCOS group were significantly increased. In order to further explore the chronic inflammatory response in the granulosa cells of PCOS rats, we continued to construct the granulosa cell inflammation model by adding LPS, and continued to detect the expression changes of the above factors. The same results were found, the expression of the above factors in LPS group was significantly higher than that in control group. Molecular biological studies on PCOS suggest that the continuous activation of chronic microinflammation is one of the molecular mechanisms closely related to the occurrence and development of the disease [46].The above results verify that the ovarian granulosa cells of PCOS rats may have a chronic inflammatory response mediated by NF-κB.

Since both telomere length and telomerase activity are important factors affecting follicular development, it has been proposed that abnormalities in the telomere/telomerase system may be one of the pathogenic mechanisms of PCOS [23]. However, the existing research results based on the relationship between PCOS and telomere/telomerase system are still controversial. Wei [22] et al. found that the telomere length of granulosa cells in PCOS patients was significantly longer than that in non-PCOS patients undergoing in vitro fertilization (IVF), however, there was no statistically significant difference in the telomere length of peripheral blood leukocytes between the two groups. Changes in telomerase activity between the two groups were not reported Pedros et al. [23] measured telomere length and telomerase activity in various cell types in ovaries of PCOS patients compared to controls with normal menstrual cycles. Women in both groups underwent in vitro fertilization with intracytoplasmic sperm injection (IVF/ICSI). It was found that the telomerase activity of cumulus granulosa cells in PCOS group was significantly higher than that in control group. However, there was no significant difference in telomere length between the two groups. In addition, Wang et al. [21] conducted a study on women aged 20–30 years and compared 40 PCOS patients with 35 non-PCOS women and found that the telomere length of granulosa cells in the PCOS group was significantly longer than that in the control group, and there was no difference in the telomere length of peripheral blood leukocytes between the two groups. This is consistent with our study that telomere length and telomerase activity are significantly increased in PCOS. Whereas the persistent oxidative stress present in PCOS patients can lead to decreased telomere stability, and proinflammatory factors and ROS may lead to shorter telomere length in leukocytes [47] and reduced telomerase activity [48]. Li [49] et al. found that the telomere length of granulosa cells in PCOS patients was shorter than that in IVF patients without PCOS, but there was no significant difference in telomerase activity between the two groups. The influence might stem from insulin resistance, and the pivotal distinction between GCs and leukocytes lies in the fact that GCs possess telomerase activity, which leukocytes lack. In addition to oxidative stress, telomerase activity is another determinant of telomere length in GCs [22, 33]. Previous findings suggest that elevated T, a hallmark of PCOS, may increase telomerase activity [50]. Telomerase is a holoenzyme composed of two basic components: TERT and TERC. TERT is a protein with reverse transcriptase activity that synthetes a hexamer sequence at the end of the chromosome and is highly expressed in renewing tissues. It represents the main component of the holoenzyme, without which there is no enzyme activity [51]. TERT is a major determinant of telomerase activity, and its expression levels are consistent with telomerase activity. Studies have found that the TRET gene can regulate persistent chronic low-grade inflammation, which in turn can influence the transcription and expression of TERT-related genes, further strengthening the cycle of inflammatory signaling pathways [52]. The p38 MAPK signaling pathway plays an indispensable role in inflammation [53]. Research has shown that the p38 MAPK pathway can not only regulate the telomere/telomerase system by activating the NF-κB signaling pathway but can also cause changes in telomere length by regulating the expression levels of the shelterin protein complex components TRF1 and TRF2 [54, 55]. Concurrently, IL-6 and TNF-α can synergistically activate STAT3, promote the physical association of STAT3 with NF-κB to form a complex, and activate the target gene hTERT. Due to the synergistic activation of STAT3, the transcription of TERT and telomerase activity increase with the activation of STAT3 and NF-κB [56]. Conversely, drugs that target the inhibition of the STAT3-TERT feedback loop can alleviate inflammation and slow disease progression [57]. Undoubtedly, the NF-κB signaling pathway is the most important pathway for regulating inflammatory responses [58]. In chronic inflammation, NF-κB has been found to exacerbate telomere dysfunction in mice [59]. Furthermore, activated NF-κB can increase the expression of TERT, and the addition of NF-κB inhibitors significantly downregulates the expression levels of TERT [60]. This indicates a positive correlation between NF-κB levels and telomerase activity. Moreover, IL-6 and TNF-α can upregulate TERT transcription and telomerase activity by activating and binding to NF-κB in macrophages [61]. This is consistent with our research findings. In this study, we investigated the expression of TERT, a key telomerase gene, in granulosa cells of PCOS rats. We found that the expression of TERT in the ovarian tissue of rats in the PCOS group was significantly upregulated compared with the control group. Therefore, we continued to verify at the cellular level, and we found that the expression of hTERT in granulosa cells was significantly up-regulated in the LPS group compared with the control group. Since LPS can induce the activation of NF-κB signaling pathway [62]. Combined with our previous results, we found that the expression of NF-κB and its downstream inflammatory factors and TERT was increased in ovarian granulosa cells of PCOS rats, and the NF-κB signaling pathway and hTERT expression were increased upon LPS induction. We further treated KGN cells with NF-κB and TERT inhibitors, and the expression of inflammatory factors and hTERT decreased. To confirm our idea, we went on to examine telomere length in ovarian cells from PCOS rats and found that telomere length was significantly longer in PCOS than in control rats. In this study, the telomere length of granulosa cells in PCOS rats was significantly longer than that in control rats, which may be due to the higher TERT activity in granulosa cells of PCOS rats. We speculate that the increased expression of TERT in ovarian granulosa cells of PCOS patients is related to the chronic inflammatory response mediated by NF-κB, and there is an interaction between the two.

Apoptosis is a physiological process of cellular clearance that is regulated by pro-apoptotic proteins belonging to the B-cell lymphoma (BCL) 2 family, BAX form transmembrane pores on the cell membrane, allowing the efflux of apoptotic factors [63]. Concurrently, the key apoptotic effector Caspase-3 can cleave and inactivate PARP, a factor involved in DNA repair [64]. Furthermore, NF-κB has been found to be activated during chronic low-grade inflammation and can control the downstream inflammatory cytokine TNF-α to mediate apoptosis. This may be a key factor leading to cellular apoptosis in chronic low-grade inflammation [65, 66]. Apoptosis plays a key role in follicular development. granulosa cells are one of the main functional cells involved in the development of follicles, and some studies have shown that a variety of clinical manifestations of PCOS patients are closely related to granulosa cell dysfunction [67]. Cataldo [68], Ding [69], Zheng [70] et al. found that the incidence of PCOS was closely related to the increase of apoptosis rate of ovarian granulosa cells. We examined the expression of Bax, Bcl-2 and Caspase-3 in the granulosa cells of PCOS rats. The results showed that Bax, Bcl-2 and Caspase-3 were expressed in the granulosa cells of PCOS rats. The expression of pro-apoptotic factors Bax and Caspase-3 in PCOS group was significantly up-regulated, and the expression of anti-apoptotic factor Bcl-2 was significantly down-regulated. Further experiments were carried out in KGN cells induced by LPS, The results showed that LPS induced significant up-regulation of Bax and Caspase-3 expression and down-regulation of Bcl-2 expression in granulosa cells. Furthermore, NF-κB inhibitor and TERT inhibitor were added to LPS-induced KGN cells, and the level of apoptosis was significantly decreased. By correlation analysis, the results showed that NF-κB and its downstream inflammatory factors and TERT were significantly correlated with apoptosis related factors in the ovarian cells of PCOS rats. At the cellular level, we obtained the same results. The above experimental results verified that the ovarian granulosa cells of PCOS had apoptosis, which was also the key cause of PCOS, and NF-κB and its downstream inflammatory factors and TERT were significantly correlated with apoptosis related factors.

Targeted drugs that address the feedback mechanism between inflammation and telomere dysfunction may offer a novel therapeutic approach for PCOS in the future. Interventions that modulate and alleviate inflammatory responses have a positive impact on telomere dysfunction in PCOS patients. For instance, studies have found that Nicotinamide mononucleotide (NMN) has anti-inflammatory properties that can improve oocyte quality [71]. However, due to limitations in specimen collection, we did not collect follicular fluid from clinical PCOS patients to verify the involvement of TERT in the regulation of the NF-κB signaling pathway. Further research is required to confirm the interactive relationship between NF-κB and TERT in the follicular fluid of clinical PCOS patients (Fig 7).

Fig 7. The NF-κB-TERT in PCOS ovarian feedback regulation mechanism of simple model.

Fig 7

TERT may participate in regulating the NF-κB signaling pathway, activating downstream inflammatory factors IL-6 and TNF-α, mediating the chronic inflammatory response of PCOS, and inducing apoptosis of ovarian granulosa cells.

Conclusion

In conclusion, this study observed a significant correlation between NF-κB-TERT feedback loop and apoptosis-related factors in ovarian granulosa cells of PCOS rats. NF-κB-TERT exhibited positive correlations with pro-apoptotic factors and negative correlations with anti-apoptotic factors. TERT may participate in the regulation of NF-κB signaling pathway and activate the downstream inflammatory factors IL-6 and TNF-α to mediate the chronic inflammatory response of PCOS and induce the apoptosis of ovarian granulosa cells. Understanding the role of the NF-κB-TERT feedback loop in the pathogenesis and progression of PCOS can aid in elucidating the specific molecular mechanisms underlying this disease and provide novel insights for the development of targeted therapeutics.

Supporting information

S1 File. The original uncropped and unadjusted images underlying all blot or gel results.

(RAR)

S2 File. The original plotting data for Fig 7.

(ZIP)

pone.0312115.s002.zip (1.5MB, zip)

Data Availability

All relevant data are within the paper and its Supporting information files.

Funding Statement

This work was supported by the Scientific Research Foundation of Hunan Provincial Education Department [20A434], The Natural Science Foundation of Guangxi in China [2020GXNSFAA297097] to SZ, The Natural Science Foundation of Hunan Province, China [2020JJ5511] to JiaZ and [2024JJ9373] to JinZ, Scientific Research Foundation of Hunan Provincial Education Department [22B0406] to JiaZ, Health Research Foundation of Hunan Provincial Health Commission Scientific Research [W20243058] to JiaZ, Foundation of Hengyang City science and technology innovation plan [202330046470] to JiaZ, and the Hunan Province Innovation and Entrepreneurship Training Program for College Students [S202310555229, S202310555214, D202305162026050688].

References

  • 1.Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018. May;14(5):270–84. doi: 10.1038/nrendo.2018.24 [DOI] [PubMed] [Google Scholar]
  • 2.Joham AE, Norman RJ, Stener-Victorin E, Legro RS, Franks S, Moran LJ, et al. Polycystic ovary syndrome. Lancet Diabetes Endocrinol. 2022. Sep;10(9):668–80. doi: 10.1016/S2213-8587(22)00163-2 [DOI] [PubMed] [Google Scholar]
  • 3.The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004. Jan 1;19(1):41–7. doi: 10.1093/humrep/deh098 [DOI] [PubMed] [Google Scholar]
  • 4.Akbarzadeh M, Naderi T, Dabbaghmanesh M. The glucose metabolism disorder and dyslipidemia among girls with different phenotype polycystic ovary syndrome. J Res Med Sci. 2019;24(1):72. doi: 10.4103/jrms.JRMS_804_16 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Diamanti-Kandarakis E. Role of obesity and adiposity in polycystic ovary syndrome. Int J Obes. 2007. Nov;31(S2):S8–13. doi: 10.1038/sj.ijo.0803730 [DOI] [PubMed] [Google Scholar]
  • 6.Wang J, Wu D, Guo H, Li M. Hyperandrogenemia and insulin resistance: The chief culprit of polycystic ovary syndrome. Life Sci. 2019. Nov;236:116940. doi: 10.1016/j.lfs.2019.116940 [DOI] [PubMed] [Google Scholar]
  • 7.González F, Rote NS, Minium J, Kirwan JP. Increased Activation of Nuclear Factor κB Triggers Inflammation and Insulin Resistance in Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2006. Apr 1;91(4):1508–12. [DOI] [PubMed] [Google Scholar]
  • 8.Zhang X, Zhang C, Shen S, Xia YJ, Yi L, Gao Q, et al. Dehydroepiandrosterone induces ovarian and uterine hyperfibrosis in female rats. Hum Reprod. 2013. Nov 1;28(11):3074–85. doi: 10.1093/humrep/det341 [DOI] [PubMed] [Google Scholar]
  • 9.Benson S, Janssen OE, Hahn S, Tan S, Dietz T, Mann K, et al. Obesity, depression, and chronic low-grade inflammation in women with polycystic ovary syndrome. Brain Behav Immun. 2008. Feb;22(2):177–84. doi: 10.1016/j.bbi.2007.07.003 [DOI] [PubMed] [Google Scholar]
  • 10.Escobar-Morreale HF, Calvo RM, Villuendas G, Sancho J, San Millán JL. Association of Polymorphisms in the Interleukin 6 Receptor Complex with Obesity and Hyperandrogenism. Obes Res. 2003. Aug;11(8):987–96. doi: 10.1038/oby.2003.136 [DOI] [PubMed] [Google Scholar]
  • 11.Liu M, Gao J, Zhang Y, Li P, Wang H, Ren X, et al. Serum levels of TSP ‐1, NF ‐κB and TGF ‐β1 in polycystic ovarian syndrome (PCOS) patients in northern China suggest PCOS is associated with chronic inflammation. Clin Endocrinol (Oxf). 2015. Dec;83(6):913–22. [DOI] [PubMed] [Google Scholar]
  • 12.Aggarwal BB, Shishodia S. Suppression of the Nuclear Factor-κB Activation Pathway by Spice-Derived Phytochemicals: Reasoning for Seasoning. Ann N Y Acad Sci. 2004. Dec;1030(1):434–41. [DOI] [PubMed] [Google Scholar]
  • 13.Lewis KA, Wuttke DS. Telomerase and Telomere-Associated Proteins: Structural Insights into Mechanism and Evolution. Structure. 2012. Jan;20(1):28–39. doi: 10.1016/j.str.2011.10.017 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Yu EY, Cheung NKV, Lue NF. Connecting telomere maintenance and regulation to the developmental origin and differentiation states of neuroblastoma tumor cells. J Hematol OncolJ Hematol Oncol. 2022. Aug 27;15(1):117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Shay JW. Role of Telomeres and Telomerase in Aging and Cancer. Cancer Discov. 2016. Jun 1;6(6):584–93. doi: 10.1158/2159-8290.CD-16-0062 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Lu W, Zhang Y, Liu D, Songyang Z, Wan M. Telomeres—structure, function, and regulation. Exp Cell Res. 2013. Jan;319(2):133–41. doi: 10.1016/j.yexcr.2012.09.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Ozturk S, Sozen B, Demir N. Telomere length and telomerase activity during oocyte maturation and early embryo development in mammalian species. Mol Hum Reprod. 2014. Jan 1;20(1):15–30. doi: 10.1093/molehr/gat055 [DOI] [PubMed] [Google Scholar]
  • 18.Shay JW, Wright WE. Senescence and immortalization: role of telomeres and telomerase. Carcinogenesis. 2005. May 1;26(5):867–74. doi: 10.1093/carcin/bgh296 [DOI] [PubMed] [Google Scholar]
  • 19.Hiyama E, Hiyama K. Telomere and telomerase in stem cells. Br J Cancer. 2007. Apr;96(7):1020–4. doi: 10.1038/sj.bjc.6603671 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Wright WE, Piatyszek MA, Rainey WE, Byrd W, Shay JW. Telomerase activity in human germline and embryonic tissues and cells. Dev Genet. 1996;18(2):173–9. doi: [DOI] [PubMed] [Google Scholar]
  • 21.Wang C, Shen F, Zhu Y, Fang Y, Lu S. Telomeric repeat-containing RNA (TERRA) related to polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf). 2017. Apr;86(4):552–9. doi: 10.1111/cen.13283 [DOI] [PubMed] [Google Scholar]
  • 22.Wei D, Xie J, Yin B, Hao H, Song X, Liu Q, et al. Significantly lengthened telomere in granulosa cells from women with polycystic ovarian syndrome (PCOS). J Assist Reprod Genet. 2017. Jul;34(7):861–6. doi: 10.1007/s10815-017-0945-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Pedroso DCC, Santana VP, Donaires FS, Picinato MC, Giorgenon RC, Santana BA, et al. Telomere Length and Telomerase Activity in Immature Oocytes and Cumulus Cells of Women with Polycystic Ovary Syndrome. Reprod Sci. 2020. Jun;27(6):1293–303. doi: 10.1007/s43032-019-00120-6 [DOI] [PubMed] [Google Scholar]
  • 24.Ghosh A, Saginc G, Leow SC, Khattar E, Shin EM, Yan TD, et al. Telomerase directly regulates NF-κB-dependent transcription. Nat Cell Biol. 2012. Dec;14(12):1270–81. [DOI] [PubMed] [Google Scholar]
  • 25.Akiyama M, Hideshima T, Hayashi T, Tai YT, Mitsiades CS, Mitsiades N, et al. Nuclear Factor-␬B p65 Mediates Tumor Necrosis Factor ␣-induced Nuclear Translocation of Telomerase Reverse Transcriptase Protein. 2003; [PubMed] [Google Scholar]
  • 26.Fontana J, Martínková S, Petr J, Žalmanová T, Trnka J. Metabolic Cooperation in the Ovarian Follicle. Physiol Res. 2020. Feb 18;33–48. doi: 10.33549/physiolres.934233 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Chi XX, Zhang T, Chu XL, Zhen JL, Zhang DJ. The regulatory effect of Genistein on granulosa cell in ovary of rat with PCOS through Bcl-2 and Bax signaling pathways. J Vet Med Sci. 2018;80(8):1348–55. doi: 10.1292/jvms.17-0001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Bernard A, Chevrier S, Beltjens F, Dosset M, Viltard E, Lagrange A, et al. Cleaved Caspase-3 Transcriptionally Regulates Angiogenesis-Promoting Chemotherapy Resistance. Cancer Res. 2019. Dec 1;79(23):5958–70. doi: 10.1158/0008-5472.CAN-19-0840 [DOI] [PubMed] [Google Scholar]
  • 29.Gong Y, Luo S, Fan P, Zhu H, Li Y, Huang W. Growth hormone activates PI3K/Akt signaling and inhibits ROS accumulation and apoptosis in granulosa cells of patients with polycystic ovary syndrome. Reprod Biol Endocrinol. 2020. Dec;18(1):121. doi: 10.1186/s12958-020-00677-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Hu CL, Cowan RG, Harman RM, Quirk SM. Cell Cycle Progression and Activation of Akt Kinase Are Required for Insulin-Like Growth Factor I-Mediated Suppression of Apoptosis in Granulosa Cells. Mol Endocrinol. 2004. Feb 1;18(2):326–38. doi: 10.1210/me.2003-0178 [DOI] [PubMed] [Google Scholar]
  • 31.Medzhitov R. Origin and physiological roles of inflammation. Nature. 2008. Jul 24;454(7203):428–35. doi: 10.1038/nature07201 [DOI] [PubMed] [Google Scholar]
  • 32.Zhang W. Linoleic acid induces human ovarian granulosa cell inflammation and apoptosis through the ER-FOXO1-ROS-NFκB pathway. Sci Rep. 2024; [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Toupance S, Fattet AJ, Thornton SN, Benetos A, Guéant JL, Koscinski I. Ovarian Telomerase and Female Fertility. Biomedicines. 2021. Jul 20;9(7):842. doi: 10.3390/biomedicines9070842 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Liang A, Huang L, Liu H, He W, Lei X, Li M, et al. Resveratrol Improves Follicular Development of PCOS Rats by Regulating the Glycolytic Pathway. Mol Nutr Food Res. 2021. Dec;65(24):2100457. doi: 10.1002/mnfr.202100457 [DOI] [PubMed] [Google Scholar]
  • 35.Huang L, Liang A, Li T, Lei X, Chen X, Liao B, et al. Mogroside V Improves Follicular Development and Ovulation in Young-Adult PCOS Rats Induced by Letrozole and High-Fat Diet Through Promoting Glycolysis. Front Endocrinol. 2022. Mar 28;13:838204. doi: 10.3389/fendo.2022.838204 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Cora MC, Kooistra L, Travlos G. Vaginal Cytology of the Laboratory Rat and Mouse: Review and Criteria for the Staging of the Estrous Cycle Using Stained Vaginal Smears. Toxicol Pathol. 2015. Aug;43(6):776–93. doi: 10.1177/0192623315570339 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Nallathambi A, Bhargavan R. Regulation of estrous cycle by Cynodon dactylon in letrozole induced polycystic ovarian syndrome in Wistars albino rats. Anat Cell Biol. 2019;52(4):511. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Liang A, Zhang W, Wang Q, Huang L, Zhang J, Ma D, et al. Resveratrol regulates insulin resistance to improve the glycolytic pathway by activating SIRT2 in PCOS granulosa cells. Front Nutr. 2023. Jan 18;9:1019562. doi: 10.3389/fnut.2022.1019562 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Maliqueo M, Benrick A, Stener-Victorin E. Rodent Models of Polycystic Ovary Syndrome: Phenotypic Presentation, Pathophysiology, and the Effects of Different Interventions. Semin Reprod Med. 2014. Apr 8;32(03):183–93. doi: 10.1055/s-0034-1371090 [DOI] [PubMed] [Google Scholar]
  • 40.Arroyo P, Ho BS, Sau L, Kelley ST, Thackray VG. Letrozole treatment of pubertal female mice results in activational effects on reproduction, metabolism and the gut microbiome. Yu Y, editor. PLOS ONE. 2019. Sep 30;14(9):e0223274. doi: 10.1371/journal.pone.0223274 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. The Lancet. 2007. Aug;370(9588):685–97. [DOI] [PubMed] [Google Scholar]
  • 42.Hamilton-Fairley Diana, Taylor Alison, Braude Peter. Anovulation. BMJ. 2003; doi: 10.1136/bmj.327.7414.546 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Garruti G, Depalo R, Vita MG, Lorusso F, Giampetruzzi F, Damato AB, et al. Adipose tissue, metabolic syndrome and polycystic ovary syndrome: from pathophysiology to treatment. Reprod Biomed Online. 2009. Oct;19(4):552–63. doi: 10.1016/j.rbmo.2009.05.010 [DOI] [PubMed] [Google Scholar]
  • 44.Deligeoroglou E, Vrachnis N, Athanasopoulos N, Iliodromiti Z, Sifakis S, Iliodromiti S, et al. Mediators of chronic inflammation in polycystic ovarian syndrome. Gynecol Endocrinol. 2012. Dec;28(12):974–8. doi: 10.3109/09513590.2012.683082 [DOI] [PubMed] [Google Scholar]
  • 45.Dabravolski SA, Nikiforov NG, Eid AH, Nedosugova LV, Starodubova AV, Popkova TV, et al. Mitochondrial Dysfunction and Chronic Inflammation in Polycystic Ovary Syndrome. Int J Mol Sci. 2021. Apr 10;22(8):3923. doi: 10.3390/ijms22083923 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.He Z, Wang Y, Zhuan L, Li Y, ouyin Tang Z, Wu Z, et al. MIF-mediated NF-κB signaling pathway regulates the pathogenesis of polycystic ovary syndrome in rats. Cytokine. 2021. Oct;146:155632. [DOI] [PubMed] [Google Scholar]
  • 47.Pedroso DCC, Miranda-Furtado CL, Kogure GS, Meola J, Okuka M, Silva C, et al. Inflammatory biomarkers and telomere length in women with polycystic ovary syndrome. Fertil Steril. 2015. Feb;103(2):542–547.e2. doi: 10.1016/j.fertnstert.2014.10.035 [DOI] [PubMed] [Google Scholar]
  • 48.Li Y, Li R, Ouyang N, Dai K, Yuan P, Zheng L, et al. Investigating the impact of local inflammation on granulosa cells and follicular development in women with ovarian endometriosis. Fertil Steril. 2019. Nov;112(5):882–891.e1. doi: 10.1016/j.fertnstert.2019.07.007 [DOI] [PubMed] [Google Scholar]
  • 49.Li Y, Deng B, Ouyang N, Yuan P, Zheng L, Wang W. Telomere length is short in PCOS and oral contraceptive does not affect the telomerase activity in granulosa cells of patients with PCOS. J Assist Reprod Genet. 2017. Jul;34(7):849–59. doi: 10.1007/s10815-017-0929-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Calado RT, Yewdell WT, Wilkerson KL, Regal JA, Kajigaya S, Stratakis CA, et al. Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells. Blood. 2009. Sep 10;114(11):2236–43. doi: 10.1182/blood-2008-09-178871 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Rocca MS, Foresta C, Ferlin A. Telomere length: lights and shadows on their role in human reproduction. Biol Reprod [Internet]. 2018. Oct 1 [cited 2023 Sep 18]; Available from: https://academic.oup.com/biolreprod/advance-article/doi/10.1093/biolre/ioy208/5113454 [DOI] [PubMed] [Google Scholar]
  • 52.Chakravarti D, Hu B, Mao X, Rashid A, Li J, Li J, et al. Telomere dysfunction activates YAP1 to drive tissue inflammation. Nat Commun. 2020. Sep 21;11(1):4766. doi: 10.1038/s41467-020-18420-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Dong C, Davis RJ, Flavell RA. MAP Kinases in the Immune Response. Annu Rev Immunol. 2002. Apr;20(1):55–72. doi: 10.1146/annurev.immunol.20.091301.131133 [DOI] [PubMed] [Google Scholar]
  • 54.Tokunaga F. Linear ubiquitination-mediated NF- B regulation and its related disorders. J Biochem (Tokyo). 2013. Oct 1;154(4):313–23. [DOI] [PubMed] [Google Scholar]
  • 55.Ludlow AT, Gratidão L, Ludlow LW, Spangenburg EE, Roth SM. Acute exercise activates p38 MAPK and increases the expression of telomere‐protective genes in cardiac muscle. Exp Physiol. 2017. Apr;102(4):397–410. doi: 10.1113/EP086189 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Chung SS, Wu Y, Okobi Q, Adekoya D, Atefi M, Clarke O, et al. Proinflammatory Cytokines IL-6 and TNF- α Increased Telomerase Activity through NF- κ B/STAT1/STAT3 Activation, and Withaferin A Inhibited the Signaling in Colorectal Cancer Cells. Mediators Inflamm. 2017;2017:1–11. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  • 57.Zhou Q, Lin L, Li H, Wang H, Jiang S, Huang P, et al. Melatonin Reduces Neuroinflammation and Improves Axonal Hypomyelination by Modulating M1/M2 Microglia Polarization via JAK2-STAT3-Telomerase Pathway in Postnatal Rats Exposed to Lipopolysaccharide. Mol Neurobiol. 2021. Dec;58(12):6552–76. doi: 10.1007/s12035-021-02568-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Kanarek N, Ben‐Neriah Y. Regulation of NF‐κB by ubiquitination and degradation of the IκBs. Immunol Rev. 2012. Mar;246(1):77–94. [DOI] [PubMed] [Google Scholar]
  • 59.Jurk D, Wilson C, Passos JF, Oakley F, Correia-Melo C, Greaves L, et al. Chronic inflammation induces telomere dysfunction and accelerates ageing in mice. Nat Commun. 2014. Jun 24;5(1):4172. doi: 10.1038/ncomms5172 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Zuo QP, Liu SK, Li ZJ, Li B, Zhou YL, Guo R, et al. NF-kappaB p65 modulates the telomerase reverse transcriptase in the HepG2 hepatoma cell line. Eur J Pharmacol. 2011. Dec;672(1–3):113–20. [DOI] [PubMed] [Google Scholar]
  • 61.Gizard F, Heywood EB, Findeisen HM, Zhao Y, Jones KL, Cudejko C, et al. Telomerase Activation in Atherosclerosis and Induction of Telomerase Reverse Transcriptase Expression by Inflammatory Stimuli in Macrophages. Arterioscler Thromb Vasc Biol. 2011. Feb;31(2):245–52. doi: 10.1161/ATVBAHA.110.219808 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Liu Y, Liu H, Li Z, Fan H, Yan X, Liu X, et al. The Release of Peripheral Immune Inflammatory Cytokines Promote an Inflammatory Cascade in PCOS Patients via Altering the Follicular Microenvironment. Front Immunol. 2021. May 17;12:685724. doi: 10.3389/fimmu.2021.685724 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Picca A, Calvani R, Coelho-Junior HJ, Marzetti E. Cell Death and Inflammation: The Role of Mitochondria in Health and Disease. Cells. 2021. Mar 3;10(3):537. doi: 10.3390/cells10030537 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Zong WX, Thompson CB. Necrotic death as a cell fate. Genes Dev. 2006. Jan 1;20(1):1–15. doi: 10.1101/gad.1376506 [DOI] [PubMed] [Google Scholar]
  • 65.Capece D, Verzella D, Flati I, Arboretto P, Cornice J, Franzoso G. NF-κB: blending metabolism, immunity, and inflammation. Trends Immunol. 2022. Sep;43(9):757–75. [DOI] [PubMed] [Google Scholar]
  • 66.Wang H, Cho CH. Effect of NF-κB signaling on apoptosis in chronic inflammation-associated carcinogenesis. Curr Cancer Drug Targets. 2010. Sep;10(6):593–9. [DOI] [PubMed] [Google Scholar]
  • 67.Shalev E. The balance between MMP-9 and MMP-2 and their tissue inhibitor (TIMP)-1 in luteinized granulosa cells: comparison between women with PCOS and normal ovulatory women. Mol Hum Reprod. 2001. Apr 1;7(4):325–31. doi: 10.1093/molehr/7.4.325 [DOI] [PubMed] [Google Scholar]
  • 68.Cataldo NA, Dumesic DA, Goldsmith PC, Jaffe RB. Immunolocalization of Fas and Fas ligand in the ovaries of women with polycystic ovary syndrome: relationship to apoptosis*. Hum Reprod. 2000. Sep;15(9):1889–97. doi: 10.1093/humrep/15.9.1889 [DOI] [PubMed] [Google Scholar]
  • 69.Ding L, Gao F, Zhang M, Yan W, Tang R, Zhang C, et al. Higher PDCD4 expression is associated with obesity, insulin resistance, lipid metabolism disorders, and granulosa cell apoptosis in polycystic ovary syndrome. Fertil Steril. 2016. May;105(5):1330–1337.e3. doi: 10.1016/j.fertnstert.2016.01.020 [DOI] [PubMed] [Google Scholar]
  • 70.Zheng Q, Li Y, Zhang D, Cui X, Dai K, Yang Y, et al. ANP promotes proliferation and inhibits apoptosis of ovarian granulosa cells by NPRA/PGRMC1/EGFR complex and improves ovary functions of PCOS rats. Cell Death Dis. 2017. Oct 26;8(10):e3145–e3145. doi: 10.1038/cddis.2017.494 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Wang L, Chen Y, Wei J, Guo F, Li L, Han Z, et al. Administration of nicotinamide mononucleotide improves oocyte quality of obese mice. doi: 10.1111/cpr.13303 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Akingbolabo Daniel Ogunlakin

20 Aug 2024

PONE-D-24-32182The mechanism of NF-κB-TERT feedback regulation of granulosa cell apoptosis in PCOS rats with follicular development disorderPLOS ONE

Dear Dr. Jiaming Zhang,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

The progression from describing the problem to presenting data and discussing the outcomes is logical and well-structured. However, the manuscript requires a revision of presentation. This includes enhancing the readability, improving the structure, and ensuring that technical terms and concepts are clearly defined. A proofreading is essential to eliminate any grammatical errors. Kindly check-up the manuscript and make the necessary changes as identified.

==============================

Please submit your revised manuscript by Oct 04 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Akingbolabo Daniel Ogunlakin, Phd

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. To comply with PLOS ONE submissions requirements, in your Methods section, please provide additional information regarding the experiments involving animals and ensure you have included details on (1) methods of sacrifice, (2) methods of anesthesia and/or analgesia, and (3) efforts to alleviate suffering.

3. Thank you for stating in your Funding Statement: 

"This work was supported by the Scientific Research Foundation of Hunan Provincial Education Department (No. 20A434), The Natural Science Foundation of Guangxi in China (No. 2020GXNSFAA297097), The Natural Science Foundation of Hunan Province, China (No. 2020JJ5511 and 2024JJ9373), Scientific Research Foundation of Hunan Provincial Education Department (No. 22B0406), Health Research Foundation of Hunan Provincial Health Commission Scientific Researchand (No. W20243058), Foundation of Hengyang City science and technology innovation plan (No. 202330046470) and the Hunan Province Innovation and Entrepreneurship Training Program for College Students (No. S202310555229, S202310555214 and D202305162026050688)."

Please provide an amended statement that declares *all* the funding or sources of support (whether external or internal to your organization) received during this study, as detailed online in our guide for authors at http://journals.plos.org/plosone/s/submit-now.  Please also include the statement “There was no additional external funding received for this study.” in your updated Funding Statement. 

Please include your amended Funding Statement within your cover letter. We will change the online submission form on your behalf.

4. In the online submission form, you indicated that [The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.]. 

All PLOS journals now require all data underlying the findings described in their manuscript to be freely available to other researchers, either 1. In a public repository, 2. Within the manuscript itself, or 3. Uploaded as supplementary information.

This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If your data cannot be made publicly available for ethical or legal reasons (e.g., public availability would compromise patient privacy), please explain your reasons on resubmission and your exemption request will be escalated for approval. 

5. When completing the data availability statement of the submission form, you indicated that you will make your data available on acceptance. We strongly recommend all authors decide on a data sharing plan before acceptance, as the process can be lengthy and hold up publication timelines. Please note that, though access restrictions are acceptable now, your entire data will need to be made freely accessible if your manuscript is accepted for publication. This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If you are unable to adhere to our open data policy, please kindly revise your statement to explain your reasoning and we will seek the editor's input on an exemption. Please be assured that, once you have provided your new statement, the assessment of your exemption will not hold up the peer review process.

6. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels.   

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions.

7. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager.

8. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section. 

9. We note that Figure 7 in your submission contain copyrighted images. All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution. For more information, see our copyright guidelines: http://journals.plos.org/plosone/s/licenses-and-copyright.

We require you to either (1) present written permission from the copyright holder to publish these figures specifically under the CC BY 4.0 license, or (2) remove the figures from your submission:

a. You may seek permission from the original copyright holder of Figure 7 to publish the content specifically under the CC BY 4.0 license. 

We recommend that you contact the original copyright holder with the Content Permission Form (http://journals.plos.org/plosone/s/file?id=7c09/content-permission-form.pdf) and the following text:

“I request permission for the open-access journal PLOS ONE to publish XXX under the Creative Commons Attribution License (CCAL) CC BY 4.0 (http://creativecommons.org/licenses/by/4.0/). Please be aware that this license allows unrestricted use and distribution, even commercially, by third parties. Please reply and provide explicit written permission to publish XXX under a CC BY license and complete the attached form.”

Please upload the completed Content Permission Form or other proof of granted permissions as an ""Other"" file with your submission. 

In the figure caption of the copyrighted figure, please include the following text: “Reprinted from [ref] under a CC BY license, with permission from [name of publisher], original copyright [original copyright year].”

b. If you are unable to obtain permission from the original copyright holder to publish these figures under the CC BY 4.0 license or if the copyright holder’s requirements are incompatible with the CC BY 4.0 license, please either i) remove the figure or ii) supply a replacement figure that complies with the CC BY 4.0 license. Please check copyright information on all replacement figures and update the figure caption with source information. If applicable, please specify in the figure caption text when a figure is similar but not identical to the original image and is therefore for illustrative purposes only.

10. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The study makes a valuable contribution to understanding the role of NFKB-TERT pathway in PCOS-related ovarian dysfunction. While the authors have conducted a thorough investigation, several considerations merit attention prior to the manuscript's acceptance.

Title: The title might feel a bit technical. Authors are encouraged to streamline the title.

Abstract:

- Technical terms could be avoided.

- Brief context should be added.

- Lack of quantitative data in the abstract.

Introduction:

- Authors are encouraged to remove redundancies, and improve transition/flowing.

- Apoptosis molecular mechanism should be expanded.

- Clearly articulate the research hypothesis.

Methodology:

- Authors must mention randomization/blinding during allocation of rats into groups.

- The study uses a well-established method to induce PCOS. It would be beneficial to add a reference.

- Were all the rats equally affected? How did the researchers ensure consistency across the PCOS group.

- Authors should mention whether the hormone levels were assessed at specific times in the oestrous cycle.

- Western blot: how was the normalization performed (which protein)? Indicate the statistical method.

- IHC: indicate the quantification method.

- Cell viability assay: specify the positive and the negative control. Replace the “ctrl” by “control”: this applies on the whole document.

Discussion:

- Lack of clarity in linking telomere length and PCOS.

- The inconsistent reporting of telomerase activity is not efficiently explained.

- While NFKB is undoubtedly important, the discussion should consider other signalling pathways (MAPK, JAK/STAT..).

- Need for detailed exploration of the specific apoptotic pathway involving Bax, bcl-2, and caspase-3. How does the pathways interact with the inflammatory signalling?

- Authors are encouraged to integrate the clinical relevance of the findings (new diagnostic criteria or targeted therapy….).

- Improve the flow between the topics.

- How does targeting theses pathways could enhance the therapeutic strategies? Discuss the potential therapies.

- Address the limitations of the study.

Conclusion: Conclusion could be improved. Figure 7 could be transferred to the end of the discussion.

Reviewer #2: The progression from describing the problem to presenting data and discussing the outcomes is logical and well-structured.

However, the manuscript requires a revision of presentation. This includes enhancing the readability, improving the structure, and ensuring that technical terms and concepts are clearly defined. A proofreading is essential to eliminate any grammatical errors.

Kindly check up the the manuscript and make the necessary changes as identified.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Amel Elbasyouni

Reviewer #2: Yes: Thomas Abu

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: PONE-D-24-32182.docx

pone.0312115.s003.docx (14.9KB, docx)
Attachment

Submitted filename: Manuscript.docx

pone.0312115.s004.docx (108.9KB, docx)
PLoS One. 2024 Oct 25;19(10):e0312115. doi: 10.1371/journal.pone.0312115.r002

Author response to Decision Letter 0


4 Sep 2024

Dear editors and reviewers,

Thank you very much for reviewing our manuscript titled “The mechanism of NF-κB-TERT feedback regulation of granulosa cell apoptosis in PCOS rats with follicular development disorder.” (PONE-D-24-32182) and for giving us an opportunity to revise the manuscript. We also greatly appreciate the reviewers for their critical review of the manuscript with thoughtful and constructive comments.

Academic Editor

Respond to these comments:

1.Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming.

Thank you very much for your suggestions. Following the editor's recommendations, we have revised the manuscript to meet the style requirements of PLOS ONE.

2.To comply with PLOS ONE submissions requirements, in your Methods section, please provide additional information regarding the experiments involving animals and ensure you have included details on (1) methods of sacrifice, (2) methods of anesthesia and/or analgesia, and (3) efforts to alleviate suffering.

Thank you very much for the editor's suggestions. We have included additional information regarding the animal experiments in the 'Methods' section to comply with PLOS ONE submission requirements. This includes details on the methods of sacrifice, anesthesia, and efforts to alleviate suffering.

3.Please provide an amended statement that declares *all* the funding or sources of support (whether external or internal to your organization) received during this study, please also include the statement “There was no additional external funding received for this study.” in your updated Funding Statement.

We sincerely appreciate your feedback. Following the editor's suggestions, we have included a revised funding statement in the Cover letter and have added the statement "There was no additional external funding received for this study." in the Funding Statement section.

4.In the online submission form, you indicated that [The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.].

Thank you very much for your suggestions. In compliance with the requirements of PLOS ONE, we have made revisions to ensure that all relevant data can be accessed within the paper and its supporting information files.

5.When completing the data availability statement of the submission form, you indicated that you will make your data available on acceptance. We strongly recommend all authors decide on a data sharing plan before acceptance, as the process can be lengthy and hold up publication timelines. Please note that, though access restrictions are acceptable now, your entire data will need to be made freely accessible if your manuscript is accepted for publication. This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If you are unable to adhere to our open data policy, please kindly revise your statement to explain your reasoning and we will seek the editor's input on an exemption. Please be assured that, once you have provided your new statement, the assessment of your exemption will not hold up the peer review process.

Thank you very much for the editor's reminder. In accordance with PLOS ONE's guidelines, we fully comply with the PLOS ONE open data policy.

6.PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files.

Thank you very much for the editor's reminder. In accordance with the requirements of PLOS ONE, we have provided all original uncropped and unadjusted images underlying all blot results in the Supporting Information section.

7.PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. 

Thank you very much for your reminder. We have now linked the corresponding author's ORCID iD.

Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section.

Thank you very much for the editor's reminder. We have removed any ethical statements that were written in sections other than the Methods section.

We note that Figure 7 in your submission contain copyrighted images. All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution.

Thank you very much for the editor's reminder. We confirm that the mechanism figure in Figure 7 was conceived and drawn by us without any copyright disputes.

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. 

We sincerely appreciate the editor's reminder. We have carefully reviewed our reference list and found that we did not cite any retracted articles.

Reviewer #1

The study makes a valuable contribution to understanding the role of NFKB-TERT pathway in PCOS-related ovarian dysfunction. While the authors have conducted a thorough investigation, several considerations merit attention prior to the manuscript's acceptance.

Respond to these comments:

1. The title might feel a bit technical. Authors are encouraged to streamline the title.

Thank you very much for the suggestions provided, which pointed out the need to reduce some professional expressions in the title to more comprehensively summarize the main theme of the article. Following the reviewer's advice, we have changed the title from "The mechanism of NF-κB-TERT feedback regulation of granulosa cell apoptosis in PCOS rats with follicular development disorder." to "The mechanism of NF-κB-TERT feedback regulation of granulosa cell apoptosis in PCOS rats."

2. Technical terms could be avoided.

Thank you very much for your suggestion. We have avoided the use of technical jargon in the abstract. We have made the correction on page 2, lines 45-47, and added the full term for the acronym LPS upon its first appearance.

3. Brief context should be added.

Thank you very much for your constructive feedback. We acknowledge that the abstract was lacking some introduction to the main topic. Following the reviewer's suggestion, we have added a 'Brief context' in the abstract section on page 2, lines 32-36, where we provide a concise overview of the relationship between inflammation and TERT in PCOS.

4. Lack of quantitative data in the abstract.

Thank you very much for your meticulous suggestions. We have enhanced the results section of the abstract by including quantitative data related to the findings, such as the magnitude of the P-values.

5. Authors are encouraged to remove redundancies, and improve transition/flowing.

Thank you very much for your feedback highlighting the need for better transitions and flow in the introduction section of our manuscript. Following your advice, we have revised the introduction to ensure a more coherent and logical progression of ideas.

6. Apoptosis molecular mechanism should be expanded.

Thank you very much for the reviewer's suggestion to include molecular mechanisms of apoptosis in the introduction, which will make the article more comprehensive. Following your advice, we have revised the introduction on pages 4, lines 99-104, and 107-109, to expand on the molecular mechanisms of apoptosis.

7. Clearly articulate the research hypothesis.

Thank you very much for the reviewer's insightful suggestion. As recommended, we have refined our research hypothesis in the introduction. We have revised the statement from "It is still not clear whether TERT can mediate chronic inflammatory response and induce granulosa cell apoptosis by participating in the regulation of NF-κB signaling pathway." to "Hence, TERT may mediate chronic inflammatory response and induce apoptosis of granulosa cells by participating in the regulation of the NF-κB signaling pathway." This change provides greater clarity and aligns with the findings of our study.

8. Authors must mention randomization/blinding during allocation of rats into groups.

hank you very much for the reviewer's careful reading, and we sincerely apologize for our oversight. Following the reviewer's suggestion, we have amended the text to "the rats were randomly divided into the control group (n = 6) and the PCOS group (n = 6)."

9. The study uses a well-established method to induce PCOS. It would be beneficial to add a reference.

We appreciate the important suggestions from the reviewer. To enhance the persuasiveness of the article, we have added references at the point where the PCOS model is induced.[1]

10. Were all the rats equally affected? How did the researchers ensure consistency across the PCOS group.

We greatly appreciate your valuable feedback. Yes, all rats were subjected to the same treatment. We ensured the consistency of the PCOS group by analyzing the estrous cycle changes through vaginal smears, the morphology of follicles through HE staining, and the changes in relevant serum hormones in the PCOS rats.

11. Authors should mention whether the hormone levels were assessed at specific times in the oestrous cycle.

We have conducted assessments of the estrous cycle and serum hormones following the methodologies outlined in the works of Zuo, Ling et al., and Ji, Rui et al., which involves the detection of serum hormones after the euthanasia of the rats. We are grateful for your valuable suggestions and plan to assess hormone levels at specific times during the estrous cycle in our future model construction.[2, 3]

12. Western blot: how was the normalization performed (which protein)? Indicate the statistical method.

Thank you very much for your valuable suggestion. We have used β-Tubulin protein for normalization. The statistical method we employed is one-way ANOVA, which has been described in the 'Statistical Analysis' section of the Materials and Methods.

13. IHC: indicate the quantification method.

We are very grateful for your reminder. Our immunohistochemistry experiments were conducted based on the methodologies from the articles of Yu, Jin et al., and Xu, Kaili et al..[4, 5] But we did not perform quantification for them. In our study, we only preliminarily explored the localization of NF-κB and its downstream inflammatory factors, apoptosis-related factors, and TERT in the ovaries. Thank you again for your important reminder; we have learned that ImageJ can be used for counting positive cells and plan to apply it in future experiments.

14. Cell viability assay: specify the positive and the negative control. Replace the “ctrl” by “control”: this applies on the whole document.

Thank you very much for your reminder. Following the reviewer's suggestion, we have revised the "Cell viability assay" section to read: "Cells were seeded in 96-well plates, with wells without cells serving as blank controls, positive controls, and different concentrations of BAY 11-7082 (0, 5, 10, and 20 μM) and BIBR1532 (0, 10, 20, 40, and 80 μM) for culture." We apologize once again for our negligence and have replaced "ctrl" with "control."

14. Lack of clarity in linking telomere length and PCOS.

Thank you very much for the suggestions provided by the reviewer. Following the reviewer's advice, we have made revisions in the discussion section. We have more clearly articulated the link between telomere length and PCOS. Studies have indicated that the telomere length of granulosa cells in PCOS patients is significantly longer than in non-PCOS patients, which is consistent with our research findings.[6]

15. The inconsistent reporting of telomerase activity is not efficiently explained.

Thank you very much for your suggestions. Although some studies have indicated that pro-inflammatory cytokines and reactive oxygen species (ROS) may lead to a decrease in telomerase activity in leukocytes of PCOS patients[7]. Our study's focus is primarily on the granulosa cells in PCOS, not leukocytes. Research has suggested that this difference may arise because granulosa cells, as actively dividing reproductive cells, have telomerase activity, which leukocytes lack[6]. Moreover, the PCOS model in our study is characterized by high testosterone levels and persistent low-grade inflammation. Previous studies have indicated that elevated testosterone, a signature marker of PCOS, may increase the activity of telomerase[8]. In response to the reviewer's feedback, we have made revisions in the discussion section to reflect these key points.

16. While NFKB is undoubtedly important, the discussion should consider other signalling pathways (MAPK, JAK/STAT..).

Thank you very much for the comments raised by the reviewer. Discussing other relevant signaling pathways will undoubtedly make our article clearer. In accordance with the reviewer's suggestions, we have made revisions on pages 16, lines 459 to 477, in the discussion section, where we further elaborated on the MAPK-TERT and STAT3-TERT feedback pathways.

17. Need for detailed exploration of the specific apoptotic pathway involving Bax, bcl-2, and caspase-3. How does the pathways interact with the inflammatory signalling?

We would like to express our gratitude for your meticulous and rigorous review. Following your suggestion, we have further discussed the apoptotic mechanisms of Bax, bcl-2, and Caspase-3, as well as how they interact with inflammatory cytokines, in the section on page 17, lines 496 to 503.

18. Authors are encouraged to integrate the clinical relevance of the findings (new diagnostic criteria or targeted therapy….).

Thank you very much for the valuable feedback from the reviewer. Relating the research findings to clinical applications can certainly enhance the readability and practical value of this paper. Following the reviewer's suggestions, we have made revisions on page 18, lines 522 to 523, where we propose new potential diagnostic targets.

19. Improve the flow between the topics.

We sincerely appreciate the valuable feedback provided by the reviewer. In accordance with the reviewer's suggestions, we have polished the manuscript to enhance the flow between topics.

20. How does targeting theses pathways could enhance the therapeutic strategies? Discuss the potential therapies.

We appreciate the suggestions made by the reviewer. Discussing potential therapeutic approaches would greatly enhance the clinical application value of this paper. Following the reviewer's advice, we have made revisions on page 18, lines 523 to 526.

21. Address the limitations of the study.

Thank you for the precious suggestions provided by the reviewer. Due to the limitations in obtaining specimens, we did not explore the regulatory relationship between TERT and NF-κB-related inflammatory factors in the follicular fluid of clinical PCOS patients. We are grateful once again for the reviewer's reminder, as this is an important part of our upcoming research. Following the reviewer's advice, we have made revisions on page 18, lines 527 to 530, where we discuss the limitations of this study.

21. Conclusion could be improved. Figure 7 could be transferred to the end of the discussion.

Thank you for the valuable suggestions provided by the reviewer. In accordance with the reviewer's comments, we have revised and enhanced the conclusion section. Additionally, we have moved Figure 7 to the end of the discussion section.

REFERENCES

1. Liang, A., et al., Resveratrol Improves Follicular Development of PCOS Rats by Regulating the Glycolytic Pathway. Molecular Nutrition & Food Research, 2021. 65(24).

2. Zuo, L., et al., Therapeutic potential of icariin in rats with letrozole and high-fat diet-induced polycystic ovary syndrome. Eur J Pharmacol, 2023. 953: p. 175825.

3. Ji, R., et al., Carnosol inhibi

Attachment

Submitted filename: Response to Reviewers.docx

pone.0312115.s005.docx (38.7KB, docx)

Decision Letter 1

Akingbolabo Daniel Ogunlakin

16 Sep 2024

The mechanism of NF-κB-TERT feedback regulation of granulosa cell apoptosis in PCOS rats

PONE-D-24-32182R1

Dear Dr. Jiaming Zhang,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Akingbolabo Daniel Ogunlakin, Phd

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Akingbolabo Daniel Ogunlakin

16 Oct 2024

PONE-D-24-32182R1

PLOS ONE

Dear Dr. Zhang,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Akingbolabo Daniel Ogunlakin

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File. The original uncropped and unadjusted images underlying all blot or gel results.

    (RAR)

    S2 File. The original plotting data for Fig 7.

    (ZIP)

    pone.0312115.s002.zip (1.5MB, zip)
    Attachment

    Submitted filename: PONE-D-24-32182.docx

    pone.0312115.s003.docx (14.9KB, docx)
    Attachment

    Submitted filename: Manuscript.docx

    pone.0312115.s004.docx (108.9KB, docx)
    Attachment

    Submitted filename: Response to Reviewers.docx

    pone.0312115.s005.docx (38.7KB, docx)

    Data Availability Statement

    All relevant data are within the paper and its Supporting information files.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES